# Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

> **NCT03674242** · PHASE2,PHASE3 · TERMINATED · sponsor: **ERYtech Pharma** · enrollment: 27 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** eryaspase (L-asparaginase encapsulated in red blood cells)
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03674242
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-13
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2022-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674242, "Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03674242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*